Dr. Kumar Discusses Study of Ixazomib in Multiple Myeloma

Shaji K. Kumar, MD
Published: Wednesday, Sep 06, 2017



Shaji K. Kumar, MD, professor of medicine, Mayo Clinic, discusses a study of ixazomib (Ninlaro) as maintenance therapy in multiple myeloma.

The current analysis focuses on the long-term outcomes of patients treated with ixazomib in combination with standard doses of lenalidomide (Revlimid) and dexamethasone, initial results of which were published 2 years ago.

The study enrolled 42 patients out of the 66 who did not go to a stem cell transplant but continued therapy with ixazomib, with a median follow-up of 55 months.
 


Shaji K. Kumar, MD, professor of medicine, Mayo Clinic, discusses a study of ixazomib (Ninlaro) as maintenance therapy in multiple myeloma.

The current analysis focuses on the long-term outcomes of patients treated with ixazomib in combination with standard doses of lenalidomide (Revlimid) and dexamethasone, initial results of which were published 2 years ago.

The study enrolled 42 patients out of the 66 who did not go to a stem cell transplant but continued therapy with ixazomib, with a median follow-up of 55 months.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x